MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bju.15925

Медицинская библиотека · BJU international · 2022

Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.

Rose Kyle M, Narang Gopal, Rosen Geoffrey, Labatte Craig, Dumitrascu Catalina I, Campagna Justin, Yu Alice, Manley Brandon J, Spiess Phillippe E, Li Roger, Adibi Mehrad, Murray Katie S, Sexton Wade J, Humphreys Mitchell R

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To assess the safety profile of antegrade mitomycin gel instillation through a percutaneous nephrostomy tube (PCNT) for upper tract urothelial carcinoma (UTUC) with the aim of decreasing morbidity associated with therapy.

PATIENTS AND

METHODS

Patients undergoing antegrade administration of mitomycin gel via PCNT were retrospectively included for analysis from four tertiary referral centres between 2020 and 2022. The primary outcome was safety profile, as graded by Common Terminology Criteria for Adverse Events (v5.0). Post-therapy disease burden was assessed by primary disease evaluation (PDE) via ureteroscopy.

RESULTS

Thirty-two patients received at least one dose of mitomycin gel via PCNT for UTUC, 29 of whom completed induction and underwent PDE. Thirteen patients (41%) had residual tumour present prior to induction therapy. At a median of 15.0 months following first dose of induction therapy, ureteric stenosis occurred in three patients (9%), all of whom were treated without later recurrence or chronic stenosis. Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and haematuria (8%). No patients had impaired renal function during follow-up and there were no treatment-related deaths. Seventeen patients (59%) had no evidence of disease at PDE and have not experienced recurrence at a median follow-up of 13.0 months post induction.

CONCLUSIONS

Administration of mitomycin gel via a PCNT offers a low rate of ureteric stenosis, demonstrates a favourable safety profile, and is administered without general anaesthesia.

Для цитирования: Rose Kyle M, Narang Gopal, Rosen Geoffrey, Labatte Craig, Dumitrascu Catalina I, Campagna Justin, Yu Alice, Manley Brandon J, Spiess Phillippe E, Li Roger, Adibi Mehrad, Murray Katie S, Sexton Wade J, Humphreys Mitchell R. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.. BJU international. 2022. DOI: 10.1111/bju.15925.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.